Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma

Arranz-Romera, Alicia; Davis, Benjamin; Bravo‐Osuna, Irene; Esteban-Pérez, Sergio; Molina‐Martínez, Irene T.; Shamsher, Ehtesham; Ravindran, Nivedita; Guo, Li; Cordeiro, M. Francesca; Herrero–Vanrell, R.

doi:10.1016/j.jconrel.2019.01.012

Cited by 76 publications

(47 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such long-acting formulations for DexSP administration can be prepared only when synthetic, non-swellable polymers are used. Such examples have been reported in literature using poly(ethylene glycol) (PEG) with zinc ion bridging [ 118 ] for DexSP nanoencapsulation and PLGA microspheres [ 119 , 120 ] where DexSP was released up to 25 and 30 days, respectively. Similar extended release profiles of Dex have been reported for intracanalicular applications (up to 30 days) [ 121 ] and up to 12 days from poly(ɛ-caprolactone) nanofibers [ 122 ].…”

Section: Resultsmentioning

confidence: 99%

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

et al. 2020

View full text Add to dashboard Cite

The aim of this work was to evaluate the effectiveness of neat chitosan (CS) and its derivatives with 2-acrylamido-2-methyl-1-propanesulfonic acid (AAMPS) and [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide (MEDSP) as appropriate nanocarriers for the simultaneous ocular administration of dexamethasone sodium phosphate (DxP) and chloramphenicol (CHL). The derivatives CS-AAMPS and CS-MEDSP have been synthesized by free-radical polymerization and their structure has been proved by Fourier-Transformed Infrared Spectroscopy (FT-IR) spectroscopy. Both derivatives exhibited low cytotoxicity, enhanced mucoadhesive properties and antimicrobial activity against Staphylococcus aureus (S.aureus) and Escherichia coli (E. coli). Encapsulation was performed via ionic crosslinking gelation using sodium tripolyphosphate (TPP) as the crosslinking agent. Dynamic light scattering measurements (DLS) showed that the prepared nanoparticles had bimodal distribution and sizes ranging from 50–200 nm and 300–800 nm. Drugs were encapsulated in their crystalline (CHL) or amorphous (DexSP) form inside nanoparticles and their release rate was dependent on the used polymer. The CHL dissolution rate was substantially enhanced compared to the neat drug and the release time was extended up to 7 days. The release rate of DexSP was much faster than that of CHL and was prolonged up to 3 days. Drug release modeling unveiled that diffusion is the main release mechanism for both drugs. Both prepared derivatives and their drug-loaded nanoparticles could be used for extended and simultaneous ocular release formulations of DexSP and CHL drugs.

show abstract

Section: Resultsmentioning

confidence: 99%

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Modulation of NMDA receptor subunits composition. [78] Recently, in an interesting approach [80] prepared PLGA 50:50 MS by the Oil/Water emulsion solvent extraction-evaporation technique including dexamethasone, melatonin and CoQ10, three recognized neuroprotective agents that were able to provide simultaneous controlled co-delivery and maintain drug concentrations above the minimum effective level and the maximum safe concentration for, at least, more than a month. When multiloaded MSs formulation were administered and the in vivo neuroprotective effect over glaucoma induction in rats (by Morrison's ocular hypertension model) evaluated, a significantly promotion of RGCs survival was found compared to administration of empty MSs.…”

Section: Curcuminmentioning

confidence: 99%

Retinal Cell Protection in Ocular Excitotoxicity Diseases. Possible Alternatives Offered by Microparticulate Drug Delivery Systems and Future Prospects

2020

View full text Add to dashboard Cite

Excitotoxicity seems to play a critical role in ocular neurodegeneration. Excess-glutamate-mediated retinal ganglion cells death is the principal cause of cell loss. Uncontrolled glutamate in the synapsis has significant implications in the pathogenesis of neurodegenerative disorders. The exploitation of various approaches of controlled release systems enhances the pharmacokinetic and pharmacodynamic activity of drugs. In particular, microparticles are secure, can maintain therapeutic drug concentrations in the eye for prolonged periods, and make intimate contact by improving drug bioavailability. According to the promising results reported, possible new investigations will focus intense attention on microparticulate formulations and can be expected to open the field to new alternatives for doctors, as currently required by patients.

show abstract

“…In a rabbit model of intravitreal glutamate toxicity, simultaneous melatonin injection could blunt the oxidative stress and improve survival of RGC by decreasing their apoptotic cell death [105]. In a recent work with a rat model of hypertensive glaucoma obtained by episcleral injection of hypersaline solution, the intravitreal administration of Poly lactic-co-glycolic acid microspheres loaded with melatonin, CoQ10 and dexamethasone releasing the drugs for over 30 days, could preserve RGC from apoptotic cell death [106]. Interestingly, not only melatonin, but also agomelatine, the novel MT1/MT2 receptor agonist antidepressant, has shown significant neuroprotective features [107].…”

Section: Food Supplementsmentioning

confidence: 99%

Food Supplements in the Treatment of Ophthalmic Diseases: Preclinical and Clinical Studies

2020

J Pharmacol Pharm Res

View full text Add to dashboard Cite

Among the 2.2 billion people in the world affected by any type of eye condition, the World Health Organization estimates 196 million with Age-related Macular Degeneration (AMD), 146 million with diabetic retinopathy (DR) and 76 million with glaucoma [1]. No clear estimate exists on the global presence of dry eye, though the English Agency known as Global-Data UK Ltd. in a document published on June 2018, considering the 8 more industrialised Countries (US,

show abstract

Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma

Abstract: Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma. Corel (2019),

Cited by 76 publications

References 92 publications

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

Retinal Cell Protection in Ocular Excitotoxicity Diseases. Possible Alternatives Offered by Microparticulate Drug Delivery Systems and Future Prospects

Food Supplements in the Treatment of Ophthalmic Diseases: Preclinical and Clinical Studies

Contact Info

Product

Resources

About